Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach